Buch, Englisch, 384 Seiten, Format (B × H): 152 mm x 229 mm
Buch, Englisch, 384 Seiten, Format (B × H): 152 mm x 229 mm
ISBN: 978-0-12-369370-9
Verlag: Academic Press
This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed. Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics, as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory boards. The expert authors represent multiple disciplines including law, medicine, bioinformatics, pharmaceutics, business, and ethics.
Zielgruppe
Advanced undergraduate and graduate students in courses focusing on biotechnology in business, law medicine, biology and public health; Managers and employees in biotech and pharmaceutical companies as well as venture capitalists and financial analysts
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Chapter 1: INTRODUCTION
Chapter 2: MERCK: STAYING THE COURSE
Chapter 3: GENZYME: PUTTING PATIENTS FIRST
Chapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES
Chapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES
Chapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS
Chapter 7: PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS
Chapter 8: TGN BIOTECH: A START-UP WITH ETHICAL ROOTS
Chapter 9: INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP
Chapter 10: SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE
Chapter 11: AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE
Chapter 12: PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD
Chapter 13: MONSANTO COMPANY: BIO-AGRICULTURE PIONEER
Chapter 14: NOVO NORDISK: THE TRIPLE BOTTOM LINE
Chapter 15: CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES
INDEX
